Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of Maryland, Baltimore
mi
from
Baltimore, MD
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of Maryland, Baltimore
mi
from
Baltimore, MD
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Children's Hospital - Boston
mi
from
Boston, MA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Children's Hospital - Boston
mi
from
Boston, MA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Boston Med Center
mi
from
Boston, MA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Boston Med Center
mi
from
Boston, MA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Mayo Clinic Rochester
mi
from
Rochester, MN
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Washington University
mi
from
St. Louis, MO
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Washington University
mi
from
St. Louis, MO
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Cornell Medical Center
mi
from
New York, NY
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Cornell Medical Center
mi
from
New York, NY
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
mi
from
New York, NY
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Strong Memorial Hospital (University of Rochester School of Medicine)
mi
from
Rochester, NY
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
The Lindner Clinical Trial Center
mi
from
Cincinnati, OH
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
The Lindner Clinical Trial Center
mi
from
Cincinnati, OH
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Cleveland Clinic Florida
mi
from
Weston, FL
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Cleveland Clinic Florida
mi
from
Weston, FL
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Case Western Reserve Univ
mi
from
Cleveland, OH
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Case Western Reserve Univ
mi
from
Cleveland, OH
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Davis Heart and Lung Research Institute
mi
from
Columbus, OH
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Davis Heart and Lung Research Institute
mi
from
Columbus, OH
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Allegheny Endocrinology Associates
mi
from
Pittsburgh, PA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Allegheny Endocrinology Associates
mi
from
Pittsburgh, PA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Rhode Island Hospital
mi
from
Providence, RI
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
mi
from
Providence, RI
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
UT Soutwestern Medical Center at Dallas
mi
from
Dallas, TX
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Baylor School of Medicine
mi
from
Houston, TX
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Baylor School of Medicine
mi
from
Houston, TX
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Intermountain Medical Center
mi
from
Murray, UT
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
Intermountain Medical Center
mi
from
Murray, UT
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
University of Virginia
mi
from
Charlottesville, VA
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension
Status: Archived
Updated: 1/1/1970
University of Virginia
mi
from
Charlottesville, VA
Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate
Comparative Effects of Nebivolol Versus Metoprolol on 24-hour Blood Pressures and Basal Metabolic Rate: An Open-Label Study
Status: Archived
University of Mississippi
mi
from
Jackson, MS
Comparing the Effects of Two Beta Blockers,Metoprolol and Nebivolol,on Ambulatory Blood Pressure and Basal Metabolic Rate
Comparative Effects of Nebivolol Versus Metoprolol on 24-hour Blood Pressures and Basal Metabolic Rate: An Open-Label Study
Status: Archived
Updated: 1/1/1970
University of Mississippi
mi
from
Jackson, MS
A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension
A Pilot Study of the Effects of Chronic Red Blood Cell Transfusion in Sickle Cell Disease On Pulmonary Hypertension in Patients With Sickle Cell Disease
Status: Archived
Duke Univ Med Ctr
mi
from
Durham, NC
A Pilot Study of Chronic Red Blood Cell Transfusion in Sickle Cell Disease-Associated Pulmonary Hypertension
A Pilot Study of the Effects of Chronic Red Blood Cell Transfusion in Sickle Cell Disease On Pulmonary Hypertension in Patients With Sickle Cell Disease
Status: Archived
Updated: 1/1/1970
Duke Univ Med Ctr
mi
from
Durham, NC
Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease
Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease
Status: Archived
University of Toledo Medical Center
mi
from
Toledo, OH
Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease
Marinobufagenin as a Target for DIGIBIND in Hypertensive Patients With End-stage Renal Disease
Status: Archived
Updated: 1/1/1970
University of Toledo Medical Center
mi
from
Toledo, OH
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Birmingham, AL
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Birmingham, AL
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Santa Clara, CA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Denver, CO
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Denver, CO
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Celebration, FL
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Celebration, FL
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Atlanta, GA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Atlanta, GA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Bettendorf, IA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Bettendorf, IA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Boston, MA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Boston, MA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Ogden, UT
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ogden, UT
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of oralBAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
Travoprost 0.004%/Timolol 0.5% Versus Timolol 0.5% in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
Status: Archived
Alcon Call Center
mi
from
Fort Worth, TX
Travoprost 0.004%/Timolol 0.5% Versus Timolol 0.5% in Chinese Patients With Open-Angle Glaucoma or Ocular Hypertension
Status: Archived
Updated: 1/1/1970
Alcon Call Center
mi
from
Fort Worth, TX
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
University of Alabama at Birmingham
mi
from
Birmingham, AL
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
Updated: 1/1/1970
University of Alabama at Birmingham
mi
from
Birmingham, AL
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
Arizona Pulmonary Specialist
mi
from
Phoenix, AZ
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
Updated: 1/1/1970
Arizona Pulmonary Specialist
mi
from
Phoenix, AZ
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
University of California, Davis Medical Center
mi
from
Sacramento, CA
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
Updated: 1/1/1970
University of California, Davis Medical Center
mi
from
Sacramento, CA
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
West Los Angeles VA Medical Center
mi
from
Los Angeles, CA
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
Updated: 1/1/1970
West Los Angeles VA Medical Center
mi
from
Los Angeles, CA
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
Updated: 1/1/1970
University of Southern California Women's and Children's Hospital
mi
from
Los Angeles, CA
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
Harbor-UCLA Med Ctr
mi
from
Torrance, CA
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
Updated: 1/1/1970
Harbor-UCLA Med Ctr
mi
from
Torrance, CA
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
Pulmonary Hypertension Clinic
mi
from
Aurora, CO
A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension (FREEDOM-C2)
Status: Archived
Updated: 1/1/1970
Pulmonary Hypertension Clinic
mi
from
Aurora, CO